Common Stock, $0.0001 par value per share
- Symbol
- MEDS
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 1.01, 7.01, 9.01 · 8-K
DataMeds AI, Inc.
MEDSNASDAQEQUITYCurrent
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On October 22, 2026, the Company issued a press release announcing that it entered into the non-binding Second A&R LOI. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference. The information in this Item 7.01, including Exhibit 99.1, is being furnished, not filed, pursuant to Regulation FD.…
Company context
We are currently not authorized to issue any shares of preferred stock. The holders of a majority of the issued and outstanding shares of our common stock approved, by written consent dated August 25, 2026, the Blank Check Amendment. Such stockholder approval will be deemed effective 20 calendar days after the date on which a definitive information statement related thereto is first sent or given to our stockholders. We filed a preliminary information statement with the SEC related thereto on August 31, 2026. As of the date of this prospectus, we have not filed a definitive information statement with the SEC or sent or given a definitive information statement to our stockholders. Promptly after the approval of the Blank Check Amendment by our stockholders is deemed effective, we expect to file the Blank Check Amendment with the Delaware Secretary of State and for it to be effective upon filing, and to promptly thereafter file a certificate of designation that designates 25,000 shares of preferred stock as the Series A Preferred Stock. Certain terms of the Series A Preferred Stock are summarized below:
Current securities
Historical securities (1)
Recent company filings
- Regulation FD Disclosure · Other EventsOct 20, 2026
- Entry into a Material Definitive Agreement · Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing · Unregistered Sales of Equity SecuritiesOct 16, 2026
- Other EventsOct 13, 2026
- PRE 14C filingOct 9, 2026
- S-1/A filingOct 9, 2026
Registered securities in this filing
DATAMEDS AI, INC. · 8-K · Filed 2026-10-26
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item
7.01 Regulation FD Disclosure.
On
October 22, 2026, the Company issued a press release announcing that it entered into the non-binding Second A&R LOI. A copy
of the press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
The
information in this Item 7.01, including Exhibit 99.1, is being furnished, not filed, pursuant to Regulation FD. Accordingly, such information
will not be incorporated by reference into any registration statement filed by the Company under the Securities Act of 1933, as amended,
unless specifically identified therein as being incorporated therein by reference. The furnishing of such information is not intended
to, and does not, constitute a determination or admission by the Company that such information is material or complete, or that investors
should consider this information before making an investment decision with respect to any security of the Company or any of its affiliates.
Filed exhibits (1)
Exhibit 99.1 DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies Proprietary IP Position Until At Least 2042 to Enable Consolidation of Infrastructure targeting market expected to grow from $9.6 billion in 2025 to $93.4 billion in 2035 Customer Acquisition Plan Leverages Existing Relationship with NFL Alumni Health Final Guidance issued by FDA Provides Roadmap for Prescription Drug Proprietary Health Lives Here™ App and DelivMeds® Software Network of 6,500 Pharmacies to Provide Nationwide Physical Healthcare Outlet TAMPA, FL / ACCESS Newswire / October 22, 2026 / DataMEDS AI, Inc. (“DataMeds SI,” “DataMEDS” or the “Company”) (NASDAQ:MEDS), a healthcare company that integrates its health information technology and physical infrastructure with its EinsteinRx ™ artificial intelligence platform and PharmacyChain™ blockchain-enabled smart contracts platform, today announced that it has entered into an amended and restated non-binding letter of intent dated October 19, 2026 (“LOI”) with Datavault AI Inc. (“Datavault AI”) (NASDAQ:DVLT), D…
Open exhibit ↗